Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: Results from the ESCALATOR study

Ali Taher, Mohsen S. Elalfy, Kusai Al Zir, Shahina Daar, Abdullah Al Jefri, Dany Habr, Ulrike Kriemler-Krahn, Bernard Roubert, Amal El-Beshlawy

Research output: Contribution to journalArticle

6 Citations (Scopus)


This analysis evaluated the effects of deferasirox on liver iron concentration in moderate and heavily iron-overloaded patients with β-thalassaemia from the ESCALATOR trial (n=231). Mean liver iron concentrations (LIC) decreased significantly from 21.1±8.2 to 14.2±12.1mg Fe/g dry weight (dw) at 2yr (P

Original languageEnglish
Pages (from-to)349-354
Number of pages6
JournalEuropean Journal of Haematology
Issue number4
Publication statusPublished - Oct 2011



  • β-thalassaemia
  • Deferasirox
  • Efficacy
  • Iron chelation therapy
  • Iron overload

ASJC Scopus subject areas

  • Hematology

Cite this